NCT00305773View on ClinicalTrials.gov

Vorinostat in Treating Patients With Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

January 31, 2010

Conditions
Adult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid LeukemiaRefractory Cytopenia With Multilineage DysplasiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

vorinostat

Given orally once daily

DRUG

vorinostat

Given orally three times daily

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00305773 - Vorinostat in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter